BEACON Pharmaceuticals Limited introduced Eltrombopag under the brand name of ETP for the treatment of thrombocytopenia.

Eltrombopag (ETP) is approved by USFDA for the following indications-

  • Thrombocytopenia in adult and pediatric patients of 1 year and older with chronic immune (idiopathic) thrombocytopenia (ITP).
  • Thrombocytopenia in patients with chronic hepatitis C.
  • Patients with severe aplastic.

ETP (Eltrombopag) is an oral tablet preparation which is available in the strengths of 25mg & 50mg. It product is manufactured in a dedicated oncology facility.